ARTICLE | Company News
Merck returns AV-299 rights to Aveo
October 1, 2010 12:13 AM UTC
Merck & Co. Inc. (NYSE:MRK) terminated a 2007 deal and returned worldwide rights to Aveo Pharmaceuticals Inc. (NASDAQ:AVEO) for cancer candidate AV-299 ( SCH 900105). Merck, which gained rights to AV-...